Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.

Unlike in the global trials, the US subgroup analysis showed similar MACE risk between vadadustat and darbepoetin in US patients with CKD not on dialysis. Among US trial participants with anemia of ...

Real-world observational data show lower cardiovascular events risks during the period leading up to dialysis initiation among erythropoietin vs roxadustat users. Erythropoietin is associated with ...

Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...